- Home
- CNMD vs TRVI Comparison
CNMD vs TRVI Comparison
Compare CNMD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNMD | TRVI |
|---|---|---|
| Founded | 1970 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNMD | TRVI |
|---|---|---|
| Price | $40.26 | $13.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $51.20 | $20.38 |
| AVG Volume (30 Days) | 447.6K | ★ 1.2M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $1,374,724,000.00 | N/A |
| Revenue This Year | $0.82 | N/A |
| Revenue Next Year | $5.48 | N/A |
| P/E Ratio | $27.57 | ★ N/A |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $35.37 | $4.85 |
| 52 Week High | $64.87 | $14.39 |
Technical Indicators
Market Signals| Indicator | CNMD | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 36.15 | 70.36 |
| Support Level | $39.36 | $10.04 |
| Resistance Level | $46.08 | $14.39 |
| Average True Range (ATR) | 1.56 | 0.69 |
| MACD | -0.52 | 0.28 |
| Stochastic Oscillator | 17.97 | 93.03 |
Price Performance
Historical ComparisonAbout CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.